Alseres Pharmaceuticals Inc (ALSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2010 | 06-2010 | 03-2010 | 12-2009 | 09-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 134 | 30 | 180 | 315 | 195 |
| Other current assets | 3 | 8 | 23 | 39 | 55 |
| TOTAL | $201 | $137 | $274 | $388 | $535 |
| Non-Current Assets | |||||
| PPE Net | 62 | 76 | 90 | 106 | 122 |
| Other Non-Current Assets | 300 | 296 | 296 | 296 | 301 |
| TOTAL | $362 | $372 | $387 | $403 | $423 |
| Total Assets | $563 | $509 | $661 | $791 | $958 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,174 | 4,070 | 3,825 | 3,523 | 3,939 |
| Accrued Expenses | 64 | 61 | 57 | 52 | 46 |
| TOTAL | $8,323 | $6,866 | $6,032 | $43,137 | $4,985 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 38,619 | 44,774 | 44,066 | 5,163 | 42,688 |
| TOTAL | $38,619 | $44,774 | $44,066 | $5,163 | $42,688 |
| Total Liabilities | $46,942 | $51,640 | $50,098 | $48,300 | $47,673 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 5 | 5 | 5 | 5 | 5 |
| Common Shares | 271 | 271 | 271 | 256 | 231 |
| Retained earnings | -193,348 | -198,181 | -196,537 | -194,678 | -192,924 |
| TOTAL | $-46,379 | $-51,131 | $-49,438 | $-47,509 | $-46,715 |
| Total Liabilities And Equity | $563 | $509 | $661 | $791 | $958 |